ArticleJournal, genetic engineering & biotechnology2025
Bioinformatics-driven identification of pathogenic missense nsSNPs in the human proto-oncogene SRC and cancer susceptibility.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational discovery of marine natural phytochemicals as novel SIRT7 inhibitors for cancer treatment.Journal, genetic engineering & biotechnology · 2026Article
- Computational screening of oncogenic genetic variations in tumor suppressor proteins driving gastric cancer pathogenesis.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SRC is a proto-oncogene that regulates cell proliferation and survival, and its dysregulation is commonly observed in diverse cancers. While SRC kinase dysregulation is well-established as a cancer driver, the functional consequences of its genetic variants, particularly non-synonymous single-nucleotide polymorphisms (nsSNPs) are not fully understood. Therefore, we employed an integrative computational approach to identify nsSNPs in SRC and analyze their impact on protein function and structure. Out of the 512 missense nsSNPs analyzed, 42 were predicted to be deleterious, with 12 likely to destabilize protein structure. Among these, three mutations, namely W151C (rs746439256), Y419N (rs2147125119), and P465S (rs1251532695), were particularly significant, causing substantial physicochemical changes. Molecular dynamics simulations revealed that these variations reduce protein stability and flexibility, resulting in conformational alterations. Docking study demonstrated that these mutations disrupt the binding interface residues of the SRC-FAK complex and affect dasatinib binding affinity. Additionally, gene expression analysis linked mutated SRC to dysregulation of cancer-related genes, especially in multiple myeloma and uterine cancer, and suggested reciprocal regulation by other mutated genes across malignancies. These findings highlight the oncogenic potential of SRC mutations and pave the way for future population-based studies exploring their role as diagnostic biomarkers, therapeutic targets, and modulators of drug response in personalized cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.